Business Context and Reporting Period
This Form 8-K Current Report was filed by Calidi Biotherapeutics, Inc. (CLDI) on June 26, 2024, covering events occurring on June 20, 2024. The Company is a Delaware corporation incorporated as an emerging growth company, with principal executive offices in San Diego, California. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed in this filing is the appointment of a new director to the Board of Directors. On June 20, 2024, the Board appointed Dr. George Peoples as a director, effective July 1, 2024. Upon appointment, Dr. Peoples will also serve as a member of the Compensation Committee. His term will expire at the Company's 2025 annual meeting of stockholders or until a successor is elected.
Outlook, Risks, and Management Commentary
Management commentary focuses on the qualifications of the new appointee. Dr. Peoples brings significant expertise in immuno-oncology and cancer vaccine development, having served 30 years as a military surgeon and research scientist. He is currently a Professor of Surgery at Uniformed Services University of the Health Sciences and a Professor of Surgical Oncology at MD Anderson Cancer Center. He has published over 300 peer-reviewed manuscripts. The filing states there are no family relationships between Dr. Peoples and existing directors or officers, and no undisclosed arrangements regarding his appointment. No specific risks, contingencies, or unusual items were disclosed in this report.
Key Facts for Investor Verification
- Dr. George Peoples' appointment as a director is effective July 1, 2024.
- Dr. Peoples will join the Compensation Committee immediately upon his appointment.
- Compensation for Dr. Peoples will be determined under the Company's standard non-employee director compensation policy (cash and/or equity).
- The filing confirms no undisclosed material interests or family relationships exist between the new director and current management.
- No financial data or operational updates regarding the Company's pipeline or cash position are included in this specific filing.